Late in infection with all herpesviruses, capsids lacking DNA and viral concatameric DNA accumulate in infected-cell nuclei. By analogy to double-stranded DNA bacteriophages, it is presumed that capsid assembly culminates when a viral terminase cleaves the concatameric DNA into genomic lengths and hydrolyzes ATP to drive the DNA through a unique structure within the capsid, termed the portal vertex. In the case of herpes simplex virus (HSV), the portal vertex is likely composed of a dodecameric ring of the U L 6 protein (pU L 6) (16, 21) .
Terminases consist of at least two subunits in all viral systems studied to date (7) . Although obtaining direct evidence for the identity of the terminase subunits in herpesviruses has been hampered by the lack of an in vitro packaging system, several lines of indirect evidence have implicated the products of U L 15 and U L 28 (pU L 15 and pU L 28, respectively) as terminase components as follows: (i) pU L 15 and pU L 28 interact in vitro and in vivo with one another and in vitro with the portal protein pU L 6 (1, 6, 11, 12, 22) , (ii) pU L 28 has been shown to bind DNA sequences necessary for formation of genomic ends (2), (iii) pU L 15 contains a highly conserved Walker box motif that is essential for HSV DNA packaging and resembles motifs maintained in the ATPase domains of some bacteriophage terminases (9, 15, 23) , and (iv) it is likely that the terminase functions are conserved, inasmuch as the homologs of pU L 15 and pU L 28 in human cytomegalovirus (hCMV), encoded by U L 89 and U L 56, respectively, which also interact, have been shown to form a complex with the hCMV portal protein and are required for DNA packaging (10, 13) .
The approximately 19,000-M r protein encoded by herpes simplex virus 1 (HSV-1) U L 33 has also been shown to interact with pU L 15 and pU L 28 by immunoprecipitation from lysates of HSV-infected cells (6) . Although its exact function is not known, pU L 33, like pU L 15 and pU L 28, is required for DNA cleavage and packaging (3, 8) . Thus, engineered mutations in any of these genes can cause empty capsids lacking DNA to accumulate in infected cells (3, 4, 20) . Small amounts of pU L 33, pU L 15, and pU L 28 have also been shown to associate with HSV-1 capsids, suggesting that they maintain their interaction during packaging (5, 18, 24) .
Because it would provide information about the HSV terminase, one goal of the present work was to characterize the roles of the individual proteins in the formation of the pU L 15/ pU L 33/pU L 28 complex.
MATERIALS AND METHODS

Cells and virus.
Vero cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum, 100 U of penicillin per ml, and 100 g of streptomycin per ml (growth medium). A U L 15 deletion virus was propagated on a cell line designated clone 17 as previously described (4) . A previously described cell line designated D4 was used to propagate the U L 33 deletion virus (17) . Clone 17 and D4 cell lines were maintained in growth medium supplemented with 500 g G418 per ml. HSV-1(F) virus and the U L 15, U L 28, and U L 33 null viruses have been described previously (4, 8, 20) . The CV28 cell line described herein was used to propagate the previously described U L 28 deletion virus (20) .
Antibodies. Polyclonal rabbit antisera recognizing the first 35 amino acids of pU L 15 (designated U L 15N), the C terminus of pU L 15, and the entire U L 28-and U L 33-encoded proteins have been described previously (6, 17, 19) . Actin antibody was purchased from Santa Cruz Biotechnology.
Plasmids. Plasmid pJB125 contained the U L 15 cDNA in vector pCDNA3 (Invitrogen), whereas plasmid pJB112 contained the U L 28 coding sequence cloned into this vector. To construct a shuttle plasmid (designated pJB401) to transfer U L 28 sequences into a defined site within CV1 cells, pJB112 was cleaved with BamHI and EcoRV, and a 2.36-kb DNA fragment containing the entire U L 28 open reading frame was isolated and cloned into pCDNA5/FRT vector (Invitrogen) at the BamHI and EcoRV sites. This vector contains the hygromycin resistance gene with an Flp recombinase targeting site (FRT site) embedded in the 5Ј coding sequence. To construct pJB433, a PCR amplicon from HSV-1(F) DNA containing the entire U L 33 coding sequence was cloned into pCDNA3 at the HindIII and EcoRI sites. pJB433 was digested with HindIII and EcoRI, and the U L 33 coding sequences were gel purified and cloned into pCDNA5/FRT at HindIII and EcoRI sites. The resultant plasmid was designated pJB481. The genotype of each plasmid was confirmed by DNA sequencing.
Transfections for transient expression. Ninety-five-percent-confluent cells were transfected with the plasmids indicated in Results by use of Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen). Cells were harvested at 24 h posttransfection and subjected to either immunoprecipitation or immunoblot analysis as described below.
Construction and maintenance of novel U L 33-and U L 28-expressing cell lines. Complementing cell lines were constructed by using the Flp-In-CV-1 system (Invitrogen) according to the manufacturer's protocol. Briefly, either pJB481 or pJB401 (see above) was cotransfected with a plasmid (pOG44) containing Flp recombinase under the control of a constitutive hCMV promoter/enhancer into an engineered cell line (Flp-CV1). This cell line was derived from CV1 cells (a derivative of Vero cells) and contains an Flp target sequence (FRT) at a single locus that also bears a lacZ gene fused to a gene encoding zeocin resistance. Transcription of the fused gene was driven by the simian virus 40 early promoter. The Flp recombination event was expected to cause insertion of the pCDNA5/ FRT construct into the cellular genome at the integrated FRT site. Insertion of the pCDNA5/FRT construct at this site was expected to bring the simian virus 40 promoter and the ATG initiation codon in frame with the hygromycin resistance gene, with concomitant inactivation of the lacZ-Zeo r fusion gene. After recombination, cells resistant to hygromycin were selected by growth in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 200 g/ml hygromycin B. Once hygromycin-resistant foci were identified, the cells were trypsinized and pooled. Monolayers of the entire population of cells containing either U L 33 or U L 28 were screened for the ability to complement the growth of the U L 33 or U L 28 null mutants, respectively. All tested cell populations were able to complement the replication of the corresponding viral null mutants (not shown), and the cells were designated CV33 and CV28, respectively. CV28 and CV33 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum, 100 U/ml penicillin, 100 g/ml streptomycin, and 200 g/ml hygromycin B.
Immunoprecipitation and immunoblotting. Cells were washed with cold phosphate-buffered saline (PBS) and resuspended in radioimmunoprecipitation assay buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA, 2 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 5 g/ml leupeptin, 10 g/ml pepstatin, 10 mM NaF, 0.1 mM Na 3 VO 4 ). After incubation on ice for 30 min without sonication, the lysates (800 l from 8.8 ϫ 10 6 cells) were clarified at 14,000 rpm for 15 min at 4°C in a microcentrifuge. The supernatants of all lysates were precleared by reaction with preimmune rabbit serum and 30 l of a 50% slurry of Gammabind G-Sepharose beads (Amersham Pharmacia Biotech) for 2 h at 4°C with constant rotation. After the beads were pelleted by centrifugation, the supernatants were incubated with rabbit antibodies directed against pU L 15, pU L 28, or pU L 33 for 2 h at 4°C. Thirty microliters of a 50% slurry of Gammabind G-Sepharose beads was then added. The mixture was incubated overnight at 4°C with constant rotation. The beads were washed four times with excess radioimmunoprecipitation assay buffer, and immune complexes were eluted in loading buffer (62.5 mM Tris, pH 6.8, 2% sodium dodecyl sulfate [SDS], 5% ␤-mercaptoethanol, 12.5% glycerol) and boiled for 10 min. The immunoprecipitated material was electrophoretically separated on 12% SDS-polyacrylamide gels, and proteins were transferred electrically to nitrocellulose. In some experiments, a portion of the lysates was denatured in loading buffer, electrophoretically separated, and transferred to nitrocellulose.
Nitrocellulose sheets were washed twice in PBS and blocked overnight in PBS supplemented with 10% nonfat dry milk (Carnation). Primary rabbit polyclonal antibodies directed against the C terminus of pU L 15 or pU L 28 were diluted 1:1,000 in PBS supplemented with 2% bovine serum albumin, whereas antipU L 33 rabbit polyclonal antibody was diluted 1:400, as previously described (17) . Actin-specific antibody was diluted 1:200 according to the manufacturer's protocol. The diluted antibodies were reacted with the blocked nitrocellulose sheets for 2 h at room temperature and washed, and horseradish peroxidase-conjugated anti-rabbit immunoglobulin G diluted 1:5,000 in PBS plus 2% bovine serum albumin was added for 2 h at room temperature. The bound immunoglobulins were revealed by enhanced chemiluminescence (Amersham Pharmacia Biotech). Where applicable, the image intensities of bands on immunoblots were quantified with a Molecular Dynamics PhosphorImager before exposure to radiographic film.
To strip and reprobe the immunoblots, developed blots were incubated in a buffer containing 62.5 mM Tris-HCl (pH 6.8), 2% SDS, and 100 mM ␤-mercaptoethanol at 50°C for 30 min as described in the ECL manual (Amersham), followed by immunoblotting as described above. (Fig. 2, lanes 1 and 2) . Reaction of HSV-1(F)-infected-cell lysates with pU L 33-specific antibody caused coimmunoprecipitation of pU L 15 (Fig. 2, lane 7) , whereas pU L 15/pU L 33 coimmunoprecipitation did not occur in lysates of cells infected with the U L 28 deletion virus (Fig. 2,  lane 3 ). These observations were consistent with previous data (Fig. 1) demonstrating that pU L 28 was necessary for the pU L 15/ pU L 33 interaction. Importantly, antibody against pU L 28 reacted with lysates of cells infected with the U L 33 deletion virus immunoprecipitated only a portion of the pU L 15 that was immunoprecipitated with its cognate antibody (compare Fig. 2, lanes 5 and 6) . These data indicate that while pU L 33 is ultimately dispensable for the pU L 15/pU L 28 interaction, it also acts in some way to enhance the interaction in infected-cell lysates.
RESULTS
To confirm some of the above results, lysates of mock-infected cells or cells infected with HSV-1(F) or the U L 15, U L 33, or U L 28 deletion virus were reacted with antibodies to these proteins, and the immunoprecipitated material was probed for the presence of pU L 28 by immunoblotting. The U L 28 protein was not immunoprecipitated from lysates of mock-infected cells or cells infected with the U L 28 deletion virus (Fig. 3, lanes  1 and 2) . In contrast, pU L 28 was readily immunoprecipitated from lysates of cells infected with wild-type virus (not shown) and deletion viruses lacking either U L 15 or U L 33 (Fig. 3, lanes  3 and 6) . Of interest was the observation that despite the presence of pU L 28 in the lysates of cells infected with the U L 33 deletion mutant, antibody to the pU L 15 N terminus coimmunoprecipitated only barely detectable levels of pU L 28 (Fig. 3,  lane 5 ). This observation further indicated that the pU L 15/ pU L 28 interaction was significantly augmented by the presence of pU L 33. Moreover, antibody directed against pU L 33 coimmunoprecipitated pU L 28 from lysates of cells infected with the U L 15 deletion mutant (Fig. 3, lane 4) , indicating that the absence of pU L 15 did not preclude an interaction between pU L 33 and pU L 28. pU L 28 is necessary and sufficient to mediate the pU L 15/ pU L 33 interaction in mammalian cells. To determine if pU L 28 was sufficient to mediate the interaction between pU L 33 and pU L 15, a cell line expressing pU L 33 was constructed as described in Materials and Methods. This cell line (CV33) was able to support replication of the U L 33 deletion mutant (data not shown). CV33 cells were transfected with plasmids expressing U L 15, U L 28, or both. Twenty-four hours later, lysates were prepared and either electrophoretically separated or immunoprecipitated with pU L 33-specific antibody, followed by electrophoretic separation on denaturing polyacrylamide gels. In both cases, separated material was transferred to nitrocellulose and analyzed for the presence of pU L 15 and pU L 28 by immunoblotting. Transfection of plasmids containing U L 15 and U L 28 into CV33 cells caused production of detectable levels of the U L 15-and U L 28-encoded proteins (Fig. 4, lanes 2 to 4) . The pU L 33-specific antibody readily coimmunoprecipitated pU L 28 from lysates of CV33 cells expressing pU L 28 or coexpressing pU L 28 and pU L 15 (Fig. 4A, lanes 6 and 8) , indicating that pU L 28 and pU L 33 can interact in the absence of other HSV proteins. In contrast, the pU L 33-specific antibody coimmuno- (␣28, lanes 1, 3, and 6 ), or pU L 33 (␣33, lanes 2 and 4). The immunoprecipitates were denatured, separated on denaturing polyacrylamide gels, and transferred onto a nitrocellulose membrane, followed by immunoblotting with pU L 28-specific polyclonal antibody. Virus and Ab indicate the infecting virus and the immunoprecipitating antibody, respectively. In the reciprocal reaction, lysates of CV33 cells that were mock transfected or transfected with plasmids expressing either U L 15 or U L 28 or both were subjected to immunoprecipitation with antibodies directed against either the N terminus of pU L 15 (Fig. 5, lanes 3 and 4) or pU L 28 (Fig. 5, lanes 1 and 2) . The presence of pU L 33 and pU L 15 in the immunoprecipitated material was then determined by immunoblotting. The U L 33-encoded protein was coimmunoprecipitated with the pU L 28-specific antibody when pU L 28 was expressed in the absence of pU L 15 (Fig. 5A, lane 2) . In contrast, and despite the presence of ample amounts of pU L 15 in U L 15N antibody-immunoprecipitated material (Fig. 5B, lane 3) , pU L 33 was coimmunoprecipitated with the pU L 15N-specific antibody only when pU L 28 was coexpressed with pU L 15 (Fig. 5A, lane 4) . These data further support the conclusion that pU L 28 is not only necessary for the pU L 33/pU L 15 interaction but also sufficient to mediate the interaction in the absence of other HSV proteins.
pU L 28 can protect pU L 33 from efficient degradation by the proteosome. Preliminary evidence indicated that pU L 33 in CV33 cells was difficult to detect by immunoblotting unless the cells were infected with wild-type HSV-1 (not shown). To determine whether the decreased amounts of pU L 33 in uninfected CV33 cells were a consequence of its proteasomal degradation or poor overall expression, CV33 cells were untreated or treated with the proteosome inhibitor MG132 or lactacystin or with a similar amount of dimethyl sulfoxide (DMSO), which was used as a carrier in the MG132 treatment. As shown in Fig. 6A , treatment with various amounts of MG132 significantly increased the amount of detectable pU L 33 in CV33 cells over levels obtained after mock treatment or treatment with DMSO. This suggested that pU L 33 within CV33 cells was efficiently degraded by the proteosome. To confirm the results, we repeated this experiment with the proteosome inhibitor lactacystin and, as controls, chloroquine (an inhibitor of the lysosomal degradation pathway) and calpain inhibitor 2 (which blocks calpain proteases). As shown in Fig. 6B , both MG132 and lactacystin substantially increased the amount of detectable pU L 33 above levels obtained in cells that were not treated, whereas chloroquine, DMSO, or calpain inhibitor 2 did not dramatically increase the levels of pU L 33. We therefore conclude that pU L 33 is efficiently degraded by the proteosome in uninfected CV33 cells.
Because the evidence presented above indicated that pU L 28 and pU L 33 interacted directly, we hypothesized that the interaction of pU L 28 with pU L 33 might increase the stability of the latter. To test this possibility, CV33 cells were transfected with expression plasmids containing U L 28, U L 15, or both, the cells were lysed 24 h later, and the presence of pU L 33 and actin (as a loading control) in the lysates was determined by immunoblotting.
As shown in Fig. 7 , the presence of pU L 28 correlated with a greatly increased level of pU L 33-specific immunoreactivity in the CV33 cells, whereas expression of pU L 15 did not increase the amount of detectable pU L 33 above that obtained upon mock transfection (compare Fig. 7A, lanes 1 to 3) . Coexpression of pU L 15 and pU L 28 also increased levels of pU L 33 immunoreactivity (Fig. 7A, lane 4) . These data indicate that U L 28 causes increased amounts of pU L 33 to accumulate in the CV33 cell line, whereas U L 15 did not induce such effects. Taken together with the knowledge that pU L 33 is normally degraded by the proteosome in CV33 cells, these data suggest that the increased stability of pU L 33 conferred by expression of pU L 28 is a consequence of the interaction of these proteins. (Fig. 7E, lanes 2 and 3) than in cells infected with either the wild-type virus (Fig. 7E, lanes 8 and 9) or the U L 15 deletion virus (Fig. 7E, lanes 5 and 6) . Moreover, lactacystin treatment increased the accumulation of pU L 33 in cells infected with the U L 28 deletion mutant (Fig. 7E, lane 4) but did not affect accumulation of pU L 33 in cells infected with wild-type HSV-1(F) (Fig. 7E, lane 9) or the U L 15 deletion The constitutively expressed U L 28 protein was immunoprecipitated from lysates of mock-transfected CV28 cells by the pU L 28-specific antibody (Fig. 8A, lane 2) and was coimmunoprecipitated with the pU L 33-specific antibody from lysates of CV28 cells expressing pU L 33 (Fig. 8A, lane 3) . The U L 28 protein of CV28 cells was not immunoprecipitated with the pU L 33-specific antibody in the absence of pU L 33 expression (Fig. 8A, lane 1) . Surprisingly, expression of U L 15 in CV28 cells followed by reaction with the pU L 15N antibody immunoprecipitated pU L 15 (Fig. 8B, lane 4) but not pU L 28 (Fig. 8A , lane 4) from CV28 cells. These data suggest that in this cell line pU L 33 augments the interaction of pU L 15 and pU L 28 in the absence of other viral proteins.
To further investigate this conclusion, a reciprocal experiment was performed. Specifically, lysates of CV28 cells that were mock transfected or transfected with expression plasmids bearing U L 33, U L 15, or both were subjected to immunoprecipitation with pU L 28-specific antibody, and the presence of pU L 15 in the immunoprecipitated material was monitored by immunoblotting. As shown in Fig. 9A , lanes 7 and 8, pU L 15 was coimmunoprecipitated with pU L 28 antibody in CV28 cells whether or not pU L 33 was expressed in the lysate; however, the presence of pU L 33 significantly augmented the coimmunoprecipitation of pU L 28 and pU L 15. To quantify the extent of this augmentation, the amounts of pU L 15 in the lysates of CV28 cells transfected with pU L 15 or pU L 15 and pU L 33 together were determined using a Molecular Dynamics PhosphorImager. The level of pU L 15 immunoreactivity in the immunoprecipitates (Fig. 9A, lanes 7 and 8) was then compared to that obtained from the lysates (Fig. 9A, lanes 3 and 4) , and a ratio of the two values was calculated (Fig. 9B) . These calculations revealed that expression of pU L 33 enhanced coimmunoprecipitation of pU L 15 and pU L 28 approximately 9.5-fold. (1, 6) . In contrast to some of the previous results, the current results with HSV-infected cells demonstrate that pU L 15 interacts with pU L 33 only upon coexpression of pU L 28. It was also of interest to note that this coexpression greatly stabilized pU L 33. This observation is consistent with the notion that the pU L 33/pU L 28 interaction precludes aberrant folding of pU L 33, thereby protecting it from targeted degradation by the proteosome. We cannot exclude the possibility that pU L 15 and pU L 33 interact directly but view it likely that such an interaction is considerably weaker than that of pU L 28 with pU L 33. Weaker interactions may be revealed more readily when proteins are highly expressed, as might have occurred in the previous study when the very strong baculovirus polyhedron promoter was used to drive gene expression (6) . Because the current study investigated the putative terminase proteins under conditions of their native environment, stoichiometry, and levels of expression, we give more credence to the current results. Because all of the interactions in both studies were identified in the context of a cell lysate, a further caveat is that other proteins may affect the interactions. Because few viral proteins other than pU L 15 and pU L 33 coimmunoprecipitate with pU L 28 (6), it seems most likely that any augmentation of the interaction would be mediated by cellular proteins or perhaps transiently by viral proteins yet to be identified.
DISCUSSION
It was of interest to find that pU L 33 augmented the interaction of pU L 15 and pU L 28 both in infected cells and when transiently expressed in uninfected mammalian cells. This represents the first identification of an activity of pU L 33 that might be relevant to its role in the HSV DNA cleavage/packaging reaction. The relatively small pU L 33 has no obvious DNA or ATP binding motifs that might be expected of a terminase subunit (14) , and this is consistent conceptually with its primary role as an adapter to augment interaction between the DNA binding (likely pU L 28) and ATPase (likely pU L 15) subunits of the terminase. Because pU L 33 interacts primarily with pU L 28, it seems most likely that pU L 33 enhances the pU L 15/pU L 28 interaction by optimizing pU L 28's capacity to bind pU L 15, perhaps by optimizing pU L 28 folding. On the other hand, given the multifunctionality of most HSV proteins it also seems likely that pU L 33 will exhibit other interesting activities upon more extensive analyses.
That the pU L 15/pU L 28/pU L 33 complex can form independently of the capsid or portal under physiological conditions in infected cells is supported by the observation here (not shown) and elsewhere that pU L 6 does not coimmunoprecipitate with pU L 15, pU L 28, or pU L 33 from infected-cell lysates (6) . Although antibodies can interfere with coimmunoprecipitations, it seems unlikely that three different antibodies to three different proteins would all fail to pull down the portal if the terminase/portal protein complex was soluble and intact. On the other hand, the lysates employed in these studies would not be expected to contain abundant amounts of nuclear proteins. If the terminase requires the portal vertex within an intranuclear procapsid for binding, as seems likely, the current studies would not be expected to detect a portal/terminase interaction because the lysates should not contain intact procapsids. That pU L 6 and putative terminase components pU L 15 and pU L 28 can interact is supported by studies using transient-expression systems (22) . Clearly, further studies of the distributions of the relevant protein complexes in HSV-infected cells are necessary to determine the sites of assembly and interaction of the putative terminase and portal encoded by pU L 6.
